BioWorld

July 24, 2002

Bayer Buying Pharmacogenomics Firm Visible Genetics For $61.4M

Bayer Corp. is scooping up Visible Genetics Inc. for $61.4 million in cash as the parties signed a definitive agreement for a deal that brings to Bayer VGI's Trugene HIV-1 Genotyping Kit and OpenGene DNA Sequencing System. (Bioworld Today) Read More

ICOS, Texas Biotechnology Stop Phase IIb/III Extension

Microarray Profiling Reveals Gene Dots Connecting Lung Carcinoma, Tumor Excision, Odds On Survival

Corvas Cuts 40 Percent Of Staff, Focuses On Late-Stage Products

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...